SRSF2 and myelodysplastic syndrome: High‐frequency mutations of SF3B1 or SRSF2 have been described in patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia, and acute myeloid leukemia (AML) (Meggendorfer et al, 2012; Donaires et al, 2016; Papaemmanuil et al, 2016).